It is the post hoc analysis of phase 2 data some time ago...... they didnt just whip out a new phase 2 whilst we werent looking - it is for this conference.
- Forums
- ASX - By Stock
- Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
It is the post hoc analysis of phase 2 data some time ago.........
-
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.02 |
Change
0.010(1.00%) |
Mkt cap ! $1.153B |
Open | High | Low | Value | Volume |
$1.00 | $1.04 | 94.0¢ | $10.61M | 10.77M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 78105 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 35590 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 57325 | 1.015 |
13 | 139963 | 1.010 |
16 | 248267 | 1.005 |
11 | 612809 | 1.000 |
5 | 39331 | 0.995 |
Price($) | Vol. | No. |
---|---|---|
1.020 | 19220 | 12 |
1.025 | 61448 | 17 |
1.030 | 115081 | 14 |
1.035 | 173976 | 13 |
1.040 | 181120 | 7 |
Last trade - 15.27pm 31/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online